Reactive species
                            
                                Human; Mouse;Rat                            
                         
                                                
                                                
                                                
                                                
                                                
                                                
                            Immunogen
                            
                                Synthesized peptide derived from human LYAG AA range: 432-482                            
                         
                                                
                            Specificity
                            
                                This antibody detects endogenous levels of LYAG at Human/Mouse/Rat                            
                         
                                                
                            Constitute
                            
                                Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.221% sodium azide.                            
                         
                                                
                            Source
                            
                                Monoclonal, Mouse,IgG                            
                         
                                                
                            Dilution rate
                            
                                WB 1:500-2000                            
                         
                                                
                            Purification process
                            
                                The antibody was affinity-purified from mouse serum by affinity-chromatography using specific immunogen.                            
                         
                                                
                                                
                                                
                            Other name
                            
                                Lysosomal alpha-glucosidase (EC 3.2.1.20) (Acid maltase) (Aglucosidase alfa) [Cleaved into: 76 kDa lysosomal alpha-glucosidase; 70 kDa lysosomal alpha-glucosidase]                            
                         
                                                
                            Background
                            
                                This gene encodes lysosomal alpha-glucosidase, which is essential for the degradation of glycogen to glucose in lysosomes. The encoded preproprotein is proteolytically processed to generate multiple intermediate forms and the mature form of the enzyme. Defects in this gene are the cause of glycogen storage disease II, also known as Pompe's disease, which is an autosomal recessive disorder with a broad clinical spectrum. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jan 2016],                            
                         
                                                
                            Function
                            
                                catalytic activity:Hydrolysis of terminal, non-reducing (1->4)-linked alpha-D-glucose residues with release of alpha-D-glucose.,caution:The sequence shown here is derived from an Ensembl automatic analysis pipeline and should be considered as preliminary data.,disease:Defects in GAA are the cause of glycogen storage disease type 2 (GSD2) [MIM:232300]; also called acid alpha-glucosidase (GAA) deficiency or acid maltase deficiency (AMD). GSD2 is a metabolic disorder with a broad clinical spectrum. The severe infantile form, or Pompe disease, presents at birth with massive accumulation of glycogen in muscle, heart and liver. Cardiomyopathy and muscular hypotonia are the cardinal features of this form whose life expectancy is less than two years. The juvenile and adult forms present as limb-girdle muscular dystrophy beginning in the lower limbs. Final outcome depends on respiratory muscle fa